Maxim Group Keeps Their Buy Rating on Agile Therapeutics (AGRX)

In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Agile Therapeutics (AGRXResearch Report), with a price target of $1.00. The company’s shares opened today at $0.32.

Rahman covers the Healthcare sector, focusing on stocks such as Agile Therapeutics, Processa Pharmaceuticals, and Viking Therapeutics. According to TipRanks, Rahman has an average return of -28.3% and a 17.58% success rate on recommended stocks.

Agile Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $2.00, representing a 525.00% upside. In a report released on December 30, H.C. Wainwright also reiterated a Buy rating on the stock with a $3.00 price target.

See today’s best-performing stocks on TipRanks >>

AGRX market cap is currently $11.33M and has a P/E ratio of -0.02.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

Read More on AGRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More